Promoter holding
64.27%
CI
Curia India Private Limited - Due diligence report
A 360° intelligence report on Albany Molecular Research: trust score, financial health, credit view, compliance, directors, growth and distr…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Albany Molecular Research — 360° Intelligence Report
Generated from MCA filings & public records79/100
Trust Score
Low Risk
Albany Molecular Research is assessed as Low Risk with a Trust Score of 79/100. Albany Molecular Research is an active private limited indian non-government company incorporated in 2005, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Curia India Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
79/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
85/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 85/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 4 open (1.10 cr) · 0 satisfied (-).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| The Cosmos Co-Operative Bank Limited | 4 | 48.0 cr |
Compliance Score: 86/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
- 3 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 55/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| MURALI KRISHNA VALLURI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| JAMES FRANCIS GRABOWSKI JR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MARIESA BETH COPPOLA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SEENA SANKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANOJ DEO DORLIKAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| Satyanarayana Tummanapalli | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 6 directors on the board.
- JAMES FRANCIS GRABOWSKI JR has DIN status "Deactivated due to non-filing of DIR-3 KYC".
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Curia Global Holdings Limited, Uk (formerly Albany Molecular Research Limited, Uk)
Subsidiaries
-
Group entities
-
Capital events
4 allotment(s) · 2 transfer(s)
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Curia Global Holdings Limited, Uk (formerly Albany Molecular Research Limited, Uk) | Holding Company | 74.00% |
| Curia Global, Inc. Usa (formerly Albany Molecular Research, Inc., Usa.) | Holding Company | 74.00% |
Key managerial personnel: MURALI KRISHNA VALLURI (Whole-time director) · MANOJ DEO DORLIKAR (Whole-time director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 21+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
4 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence81/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment82/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 4 open charge(s) of 1.10 cr already registered.
- Compliance record supports lending.
Investor view80/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management churn warrants questions.
09
MCA Filings & Events Timeline
Latest 15 events29 Sep 2025
Last AGM held
Annual general meeting
18 Sep 2025
Director appointed
Satyanarayana Tummanapalli (Whole-Time Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
12 Jul 2023
Director appointed
MANOJ DEO DORLIKAR (Whole-time director)
01 Jul 2023
Director ceased
Abhinav Arora
29 Sep 2022
Director ceased
JAMES FRANCIS GRABOWSKI JR
14 Jul 2022
Director ceased
GUDAPARTHI OMPRAKASH
15 Dec 2021
Director appointed
JAMES FRANCIS GRABOWSKI JR (Director)
28 Nov 2018
Director ceased
MARIESA BETH COPPOLA
23 Nov 2018
Securities allotted
2384653 Equity Shares - 23.85 cr raised
Director appointed
SEENA SANKAR (Company Secretary)
28 Aug 2018
Director ceased
ANAND KUMAR JAIN
10 Jul 2018
Director ceased
ANURAG RASTRANAYAKA
13 Dec 2017
Director appointed
MARIESA BETH COPPOLA (Director)
06 Dec 2017
Director ceased
LORI MARIE HENDERSON
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
6 active director(s) / partner(s); review board churn before relying on management continuity.
3 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| Ambica Dhatu Pvt. Ltd. | U27209WB1992PTC056001 | Kolkata, West Bengal, India |
| Admark Polycoats Private Limited | U24224GJ2002PTC040987 | Vadodara, Gujarat, India |
| Virchow | U24239TG2004PLC042949 | Hyderabad, Telangana, India |
| Blue Heaven | U24246MH2002PTC411209 | Mumbai, Maharashtra, India |
| Rakspharma | U24233GJ2008PTC068526 | Ahmedabad, Gujarat, India |
| Arora Aromatics | U20293DL2012PTC234522 | New Delhi, Delhi, India |
| Cygnet Industries Limited | U74900WB2015PLC206720 | Kolkata, West Bengal, India |
| Star Chemicals (Bombay) Private Limited | U24100MH1962PTC012351 | Mumbai, Maharashtra, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Albany Molecular Research before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Albany Molecular Research: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 85/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Albany Molecular Research - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 79/100, distress signals and MSME payment-delay disclosures - know whether Albany Molecular Research pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Albany Molecular Research - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Albany Molecular Research an active company?
Albany Molecular Research has MCA status “Active” with a compliance score of 86/100 (Low Risk).
Is Albany Molecular Research financially healthy?
Albany Molecular Research has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.
Should I do business with Albany Molecular Research?
Its overall Trust Score is 79/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Albany Molecular Research?
The ultimate holding entity is Curia Global Holdings Limited, Uk (formerly Albany Molecular Research Limited, Uk). 6 active director(s) are on record.
Does Albany Molecular Research have loans or charges against its assets?
4 open charge(s) are registered against its assets.
Is Albany Molecular Research up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).
Is it risky to lend to Albany Molecular Research?
Its Credit Risk Score is 85/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
